Tremlett Helen L, Oger Joel
Division of Neurology, Department of Medicine, University of British Columbia, Vancouver Hospital and Health Sciences Center, Canada.
Neurology. 2003 Aug 26;61(4):551-4. doi: 10.1212/01.wnl.0000078885.05053.7d.
A retrospective chart review of patients in British Columbia with multiple sclerosis prescribed beta-interferon (IFNbeta) between 1995 and 2001 was carried out to investigate reasons for the interruption of therapy. The highest proportion of interruptions (76/281; 27%) occurred in the first 6 months. The single most common reason was perceived lack of efficacy, cited by 84 of 281 (30%). Gender, disability, and disease duration were identified as factors influencing interruption of IFNbeta therapy.
对1995年至2001年间在不列颠哥伦比亚省接受β-干扰素（IFNβ）治疗的多发性硬化症患者进行了一项回顾性病历审查，以调查治疗中断的原因。中断比例最高的（76/281；27%）发生在前6个月。最常见的单一原因是认为缺乏疗效，281例中有84例（30%）提到这一点。性别、残疾程度和病程被确定为影响IFNβ治疗中断的因素。
